RxDoctor Payments Data

William McMillan, MD

Family Medicine · Jamestown, NDNPI 1831117415

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Amgen at 24.3% of the total. Reporting peaked in 2019 at $367 and has fallen 91.5% since, to $31 in 2025.

$1,155in general payments, 2019–2025

Across 80 payments — averaging $14.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$280
  • Pfizer$75
  • Johnson & Johnson$74
  • Regeneron Healthcare Solutions, Inc.$70
  • AbbVie$67
  • Dexcom, Inc.$61
  • plus $527 from 20 others

What the payments were for

  • Food & beverage$1,155100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,155 in reported general payments places this provider in the 85th percentile of 337 family medicine providers in North Dakota.

See all family medicine providers in North Dakota

Medicare billing

Part B allowed, 2024
$10,346
Medicare patients
99
Services billed
196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Victoza 3-PakLiraglutide11$9,517
XareltoRivaroxaban29$9,460
Levothyroxine Sodium26$248
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav19$106
Doxycycline Hyclate30$103
Hydrochlorothiazide19$93
Prednisone12$17

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$74$9,46029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 337 family medicine providers in North Dakota.

Other family medicine in Jamestown

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →